{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:20:50Z","timestamp":1790104850045,"version":"4.0.1"},"reference-count":27,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2008,5,7]],"date-time":"2008-05-07T00:00:00Z","timestamp":1210118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Hellenic Neurological Society (ENEE)"},{"name":"Pitzer Foundation"},{"name":"German Ministry of Education and Research","award":["DLR 01GO0203"],"award-info":[{"award-number":["DLR 01GO0203"]}]},{"name":"WHO","award":["BMBF-01GI0401"],"award-info":[{"award-number":["BMBF-01GI0401"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["ZA233\/1-1"],"award-info":[{"award-number":["ZA233\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["HO2402\/6-1"],"award-info":[{"award-number":["HO2402\/6-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MSE Pharmazeutika, Bad Homburg, Germany"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2008,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mitochondrial complex I appears to be dysfunctional in progressive supranuclear palsy (PSP). Coenzyme Q<jats:sub>10<\/jats:sub> (CoQ<jats:sub>10<\/jats:sub>) is a physiological cofactor of complex I. Therefore, we evaluated the short\u2010term effects of CoQ<jats:sub>10<\/jats:sub> in PSP. We performed a double\u2010blind, randomized, placebo\u2010controlled, phase II trial, including 21 clinically probable PSP patients (stage \u2264 III) to receive a liquid nanodispersion of CoQ<jats:sub>10<\/jats:sub> (5 mg\/kg\/day) or matching placebo. Over a 6\u2010week period, we determined the change in CoQ<jats:sub>10<\/jats:sub> serum concentration, cerebral energy metabolites (by <jats:sup>31<\/jats:sup>P\u2010 and <jats:sup>1<\/jats:sup>H\u2010magnetic resonance spectroscopy), motor and neuropsychological dysfunction (PSP rating scale, UPDRS III, Hoehn and Yahr stage, Frontal Assessment Battery, Mini Mental Status Examination, Montgomery \u00c5sberg Depression Scale). CoQ<jats:sub>10<\/jats:sub> was safe and well tolerated. In patients receiving CoQ<jats:sub>10<\/jats:sub> compared to placebo, the concentration of low\u2010energy phosphates (adenosine\u2010diphosphate, unphosphorylated creatine) decreased. Consequently, the ratio of high\u2010energy phosphates to low\u2010energy phosphates (adenosine\u2010triphosphate to adenosine\u2010diphosphate, phospho\u2010creatine to unphosphorylated creatine) increased. These changes were significant in the occipital lobe and showed a consistent trend in the basal ganglia. Clinically, the PSP rating scale and the Frontal Assessment Battery improved slightly, but significantly, upon CoQ<jats:sub>10<\/jats:sub> treatment compared to placebo. Since CoQ<jats:sub>10<\/jats:sub> appears to improve cerebral energy metabolism in PSP, long\u2010term treatment might have a disease\u2010modifying, neuroprotective effect. \u00a9 2008 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.22023","type":"journal-article","created":{"date-parts":[[2008,5,7]],"date-time":"2008-05-07T19:16:38Z","timestamp":1210187798000},"page":"942-949","source":"Crossref","is-referenced-by-count":129,"title":["Short\u2010term effects of coenzyme Q<sub>10<\/sub> in progressive supranuclear palsy: A randomized, placebo\u2010controlled trial"],"prefix":"10.1002","volume":"23","author":[{"given":"Maria","family":"Stamelou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Reuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Pilatus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Magerkurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Niklowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla M.","family":"Eggert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Krisp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Menke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Schade\u2010Brittinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang H.","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter U.","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,5,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.1.1"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(02)00161-8"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm032"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-006-0012-z"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410240308"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200009)15:5<889::AID-MDS1020>3.0.CO;2-T"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)10166-6"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2000.0751681.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-0186(01)00126-7"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.02.002"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2003.01533.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2003.02138.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2005.03493.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1644-07.2007"},{"key":"e_1_2_6_16_2","first-page":"536","article-title":"Pharmacokinetic study of deuterium\u2010labelled coenzyme Q10 in man","volume":"24","author":"Tomono Y","year":"1986","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_2_6_17_2","first-page":"A326","article-title":"A clinical rating scale and staging system for progressive supranuclear palsy","volume":"48","author":"Golbe LI","year":"1997","journal-title":"Neurology"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.7.nct60005"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","article-title":"Effects of coenzyme Q10 in early Parkinson disease. Evidence of slowing of the functional decline","volume":"59","author":"Shults CW","year":"2002","journal-title":"Arch Neurol"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.11.1621"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1006\/abio.2000.4579"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2290141"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2005.03.012"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jcbfm.9600192"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/123.2.340"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.6.892"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1001"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(03)00185-X"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.22023","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.22023","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.22023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:48:10Z","timestamp":1760957290000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.22023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,5,15]]}},"alternative-id":["10.1002\/mds.22023"],"URL":"https:\/\/doi.org\/10.1002\/mds.22023","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,7]]}}}